Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta And Tyrosinase Related Protein 1
Clinical Stage III Cutaneous Melanoma AJCC v8
Mayo Clinicgene_therapyPhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
28 Active assets in the Clinical Stage III Cutaneous Melanoma AJCC v8 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ipilimumab Amsterdam UMC, location VUmc | Phase 3 | BB |
Nivolumab Fred Hutchinson Cancer Center | Phase 3 | BB |
Atezolizumab EuroCityClinic LLC | Phase 2 | BB |
INTERFERON ALFA-2B National Cancer Institute (NCI) | Phase 3 | B |
Tocilizumab M.D. Anderson Cancer Center | Phase 2 | B |
View all 38 →
Same molecule, other indications
Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta And Tyrosinase Related Protein 1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →